Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Aminocaproic Acid, Bleeding Complications Assessed

Leuk Lymphoma; ePub 2018 Feb 9; Juhl, Roddy, et al

Aminocaproic acid does not seem to lead to a high incidence of thromboembolic complications in people with hematologic malignancies, researchers concluded after conducting a retrospective study involving 109 individuals. Participants with hematologic malignancies had received aminocaproic acid to prevent/treat of thrombocytopenic hemorrhage. Investigators looked for thromboembolic complications confirmed by imaging studies. Among the results:

  • 5% of patients experienced thromboembolic complications; all were venous thromboses.
  • These patients had additional risk factors, such as central venous catheters.

The author noted that the concurrent risk factors may have played a role in thromboses.

Citation:

Juhl R, Roddy J, Wang T, Li J, Elefritz J. Thromboembolic complications following aminocaproic acid use in patients with hematologic malignancies. [Published online ahead of print February 9, 2018]. Leuk Lymphoma. doi:10.1080/10428194.2018.1434882.

This Week's Must Reads

Widespread Zika screens not cost effective, Saá P et al. New Engl J Med. 2018;378:1778-88. doi: 10.1056/NEJMoa1714977

New cancer drugs linked to fewer arrhythmias, Nickel A et al. annual meeting of the American College of Cardiology ACC 18, Abstract #900-06.

Good ALL outcomes in Down syndrome children, Maloney K et al. ASPHO 2018, annual meeting of the American Society of Pediatric Hematology/Oncology Abstract PP 2001

Reducing morbidity in postpartum hemorrhage, Smith R et al. Annual clinical and scientific meeting of the American Society of Obstetricians and Gynecologists 2018, Abstract 26R.

In sickle cell, start hydroxyurea in infancy, Schuchard S et al. ASPHO 2018, poster # 342 Schuchard S et al. ASPHO 2018, poster # 342. https://onlinelibrary.wiley.com/doi/10.1002/pbc.27057

Must Reads in Bleeding Disorders

Reducing morbidity in postpartum hemorrhage, Smith R et al. Annual clinical and scientific meeting of the American Society of Obstetricians and Gynecologists 2018, Abstract 26R.

In sickle cell, start hydroxyurea in infancy, Schuchard S et al. ASPHO 2018, poster # 342 Schuchard S et al. ASPHO 2018, poster # 342. https://onlinelibrary.wiley.com/doi/10.1002/pbc.27057

Increase kidney function monitoring if INR exceeds 4.0, Traquair H et al. biennial summit of the Thrombosis & Hemostasis Societies of North America 2018, Poster 79.

Vaccination lags in children with sickle cell disease, Wagner AL et al. J Pediatr. 2018 May;196:223-9.

Idarucizumab reversed dabigatran despite severe renal dysfunction, Eikelboom JW et al. ACC 18, the annual meeting of the American College of Cardiology, Abstract 1231M-11.